<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35316977</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2157-1724</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Kidney international supplements</Title><ISOAbbreviation>Kidney Int Suppl (2011)</ISOAbbreviation></Journal><ArticleTitle>The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets.</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>62</EndPage><MedlinePgn>48-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.kisu.2021.12.001</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19) pandemic, causing considerable mortality and morbidity worldwide, has fully engaged the biomedical community in attempts to elucidate the pathophysiology of COVID-19 and develop robust therapeutic strategies. To this end, the predominant research focus has been on the adaptive immune response to COVID-19 infections stimulated by mRNA and protein vaccines and on the duration and persistence of immune protection. In contrast, the role of the innate immune response to the viral challenge has been underrepresented. This overview focuses on the innate immune response to COVID-19 infection, with an emphasis on the roles of extracellular proteases in the tissue microenvironment. Proteinase-mediated signaling caused by enzymes in the extracellular microenvironment occurs upstream of the increased production of inflammatory cytokines that mediate COVID-19 pathology. These enzymes include the coagulation cascade, kinin-generating plasma kallikrein, and the complement system, as well as angiotensin-generating proteinases of the renin-angiotensin system. Furthermore, in the context of several articles in this Supplement elucidating and detailing the trajectory of diverse profibrotic pathways, we extrapolate these insights to explore how fibrosis and profibrotic pathways participate importantly in the pathogenesis of COVID-19. We propose that the lessons garnered from understanding the roles of microenvironment proteinases in triggering the innate immune response to COVID-19 pathology will identify potential therapeutic targets and inform approaches to the clinical management of COVID-19. Furthermore, the information may also provide a template for understanding the determinants of COVID-19-induced tissue fibrosis that may follow resolution of acute infection (so-called "long COVID"), which represents a major new challenge to our healthcare systems.</AbstractText><CopyrightInformation>&#xa9; 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hollenberg</LastName><ForeName>Morley D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology &amp; Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epstein</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Kidney Int Suppl (2011)</MedlineTA><NlmUniqueID>101562008</NlmUniqueID><ISSNLinking>2157-1716</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">fibrosis</Keyword><Keyword MajorTopicYN="N">innate immune response</Keyword><Keyword MajorTopicYN="N">proteases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>5</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35316977</ArticleId><ArticleId IdType="pmc">PMC8931295</ArticleId><ArticleId IdType="doi">10.1016/j.kisu.2021.12.001</ArticleId><ArticleId IdType="pii">S2157-1716(21)00063-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ Accessed January 13, 2022.</Citation></Reference><Reference><Citation>The Economist. Covid-19 data: the pandemic&#x2019;s true death toll. https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates Accessed January 13, 2022.</Citation></Reference><Reference><Citation>Antonelli M., Penfold R.S., Merino J., et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study. app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Glatman-Freedman A., Bromberg M., Dichtiar R., et al. The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: a nation-wide retrospective longitudinal multiple cohort analysis using individualised data. EBioMedicine. 2021;72:103574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445746</ArticleId><ArticleId IdType="pubmed">34537449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.H., Hotez P., Batista C., et al. Operation Warp Speed: implications for global vaccine security. Lancet Global Health. 2021;9:e1017&#x2013;e1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997645</ArticleId><ArticleId IdType="pubmed">33780663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, et&#xa0;al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385:1474&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Niyas V.K.M., Arjun R. Correspondence: breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine. QJM. 2021;114:757&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">34117884</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay M.Z., Poh C.M., R&#xe9;nia L., et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K., Avidan M.S., Benn C.S., et al. Old vaccines for new infections: exploiting innate immunity to control COVID-19 and prevent future pandemics. Proc Natl Acad Sci U S A. 2021;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8166166</ArticleId><ArticleId IdType="pubmed">34006644</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov K., Benn C.S., Aaby P., et al. Can existing live vaccines prevent COVID-19? Science. 2020;368:1187&#x2013;1188.</Citation><ArticleIdList><ArticleId IdType="pubmed">32527819</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M., Martin J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20:355&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam H.Y., Tergaonkar V., Kumar A.P., Ahn K.S. Mast cells: therapeutic targets for COVID-19 and beyond. IUBMB Life. 2021;73:1278&#x2013;1292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652840</ArticleId><ArticleId IdType="pubmed">34467628</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze J.L., Aschenbrenner A.C. COVID-19 and the human innate immune system. Cell. 2021;184:1671&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7885626</ArticleId><ArticleId IdType="pubmed">33743212</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran R., Noorbakhsh F., Defea K., et al. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">22212680</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhoff M., Buddenkotte J., Shpacovitch V., et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev. 2005;26:1&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15689571</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuberger D.M., Schuepbach R.A. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J. 2019;17:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440139</ArticleId><ArticleId IdType="pubmed">30976204</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrario C.M., Groban L., Wang H., et al. The renin&#x2013;angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts. Kidney Int Suppl. 2022;12:36&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073260</ArticleId><ArticleId IdType="pubmed">35529089</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhoff M., Vergnolle N., Young S.H., et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655102</ArticleId></ArticleIdList></Reference><Reference><Citation>Organisation for Economic Co-operation and Development (OECD)  Access to COVID-19 vaccines: global approaches in a global crisis. https://www.oecd.org/coronavirus/policy-responses/access-to-covid-19-vaccines-global-approaches-in-a-global-crisis-c6a18370/ Accessed November 12, 2021.</Citation></Reference><Reference><Citation>Hazeldine J., Lord J.M. Immunesenescence: a predisposing risk factor for the development of COVID-19? Front Immunol. 2020;11:573662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7573102</ArticleId><ArticleId IdType="pubmed">33123152</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Zhao K., Shi Z.L., Zhou P. Bat coronaviruses in China. Viruses. 2019;11:210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6466186</ArticleId><ArticleId IdType="pubmed">30832341</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls A.C., Park Y.J., Tortorici M.A., et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181:281&#x2013;292.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102599</ArticleId><ArticleId IdType="pubmed">32155444</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Guo Y., Pan Y., et al. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525:135&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092824</ArticleId><ArticleId IdType="pubmed">32081428</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Moore M.J., Vasilieva N., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson S., Greer B., Hooper J., et al. The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. Biochem J. 2005;388:967&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183478</ArticleId><ArticleId IdType="pubmed">15537383</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N., Samstein R., Fernandez N., et al. Advancing scientific knowledge in times of pandemics. Nat Rev Immunol. 2020;20:338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7187143</ArticleId><ArticleId IdType="pubmed">32327718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Chen X., Cai Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Tan Y., Ling Y., et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. 2020;583:437&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">32434211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.G., Simpson L.J., Ferreira A.M., et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 2020;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526438</ArticleId><ArticleId IdType="pubmed">32706339</ArticleId></ArticleIdList></Reference><Reference><Citation>Remy K.E., Mazer M., Striker D.A., et al. Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight. 2020;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526441</ArticleId><ArticleId IdType="pubmed">32687484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolodny O., Berger M., Feldman M.W., et al. A&#xa0;new perspective for mitigation of SARS-CoV-2 infection: priming the innate immune system for viral attack. Open Biol. 2020;10:200138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574546</ArticleId><ArticleId IdType="pubmed">36416599</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.C., Zhang J., Zhuo J.L. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125:21&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5607101</ArticleId><ArticleId IdType="pubmed">28619367</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia G., Habibi J., Aroor A.R., et al. Epithelial sodium channel in aldosterone-induced endothelium stiffness and aortic dysfunction. Hypertension. 2018;72:731&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202124</ArticleId><ArticleId IdType="pubmed">29987101</ArticleId></ArticleIdList></Reference><Reference><Citation>Danser A.H.J., Epstein M., Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7225046</ArticleId><ArticleId IdType="pubmed">32208987</ArticleId></ArticleIdList></Reference><Reference><Citation>South A.M., Brady T.M., Flynn J.T. ACE2 (angiotensin-converting enzyme 2), COVID-19, and ACE inhibitor and Ang II (angiotensin II) receptor blocker use during the pandemic: the pediatric perspective. Hypertension. 2020;76:16&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289676</ArticleId><ArticleId IdType="pubmed">32367746</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J.B., Hanff T.C., William P., et al. Continuation versus discontinuation of renin&#x2013;angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832152</ArticleId><ArticleId IdType="pubmed">33422263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G., Rea F., Ludergnani M., et al. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. N&#xa0;Engl J Med. 2020;382:2431&#x2013;2440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206933</ArticleId><ArticleId IdType="pubmed">32356627</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds H.R., Adhikari S., Pulgarin C., et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N&#xa0;Engl J Med. 2020;382:2441&#x2013;2448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206932</ArticleId><ArticleId IdType="pubmed">32356628</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S., Hirsch J.S., Narasimhan M., et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks M.A., South A., Welling P., et al. Sound science before quick judgement regarding RAS blockade in COVID-19. Clin J Am Soc Nephrol. 2020;15:714&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269218</ArticleId><ArticleId IdType="pubmed">32220930</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang G., Tan Z., Zhou L., et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension. 2020;76:51&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">32348166</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Mart&#xed;nez E., Buonafine M., Boukhalfa I., et al. Aldosterone target NGAL (neutrophil gelatinase-associated lipocalin) is involved in cardiac remodeling after myocardial infarction through NF&#x3ba;B pathway. Hypertension. 2017;70:1148&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">29061727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauersachs J., Lother A. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl. 2022;12:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073241</ArticleId><ArticleId IdType="pubmed">35529088</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata S., Nagase M., Yoshida S., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14:1370&#x2013;1376.</Citation><ArticleIdList><ArticleId IdType="pubmed">19029984</ArticleId></ArticleIdList></Reference><Reference><Citation>Taye A., Morawietz H. Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells. Iran J Pharm Res. 2011;10:329&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828907</ArticleId><ArticleId IdType="pubmed">24250362</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwashima F., Yoshimoto T., Minami I., et al. Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology. 2008;149:1009&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pubmed">18079208</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashikabe Y., Suzuki K., Jojima T., et al. Aldosterone impairs vascular endothelial cell function. J&#xa0;Cardiovasc Pharmacol. 2006;47:609&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pubmed">16680076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata D., Takahashi M., Sawai K., et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006;48:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">16754797</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes J.L., Gorin Y. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int. 2011;79:944&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3675765</ArticleId><ArticleId IdType="pubmed">21307839</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura T., Girerd S., Jaisser F., Barrera-Chimal J. Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney Int Suppl. 2022;12:12&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073223</ArticleId><ArticleId IdType="pubmed">35529084</ArticleId></ArticleIdList></Reference><Reference><Citation>Luther J.M., Fogo A.B. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int Suppl. 2022;12:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073221</ArticleId><ArticleId IdType="pubmed">35529087</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnard B., Martinez-Martinez E., Fernandez-Celis A., et al. Antifibrotic&#xa0;effect of novel neutrophil gelatinase-associated lipocalin&#xa0;inhibitors in cardiac and renal disease models. Sci Rep. 2021;11:2591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7844219</ArticleId><ArticleId IdType="pubmed">33510370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran R., Altier C., Oikonomopoulou K., et al. Proteinases, their extracellular targets, and inflammatory signaling. Pharmacol Rev. 2016;68:1110&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">27677721</ArticleId></ArticleIdList></Reference><Reference><Citation>Abassi Z., Skorecki K., Hamo-Giladi D.B., et al. Kinins and chymase: the forgotten components of the renin-angiotensin system and their implications in COVID-19 disease. Am J Physiol Lung Cell Mol Physiol. 2021;320:L422&#x2013;L429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7938643</ArticleId><ArticleId IdType="pubmed">33404363</ArticleId></ArticleIdList></Reference><Reference><Citation>McFadyen J.D., Stevens H., Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127:571&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7386875</ArticleId><ArticleId IdType="pubmed">32586214</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini D., Kawakami R., Guagliumi G., et al. Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. Circulation. 2021;143:1031&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">33480806</ArticleId></ArticleIdList></Reference><Reference><Citation>Poor H.D., Ventetuolo C.E., Tolbert T., et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med. 2020;10:e44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7288983</ArticleId><ArticleId IdType="pubmed">32508062</ArticleId></ArticleIdList></Reference><Reference><Citation>Garvin M.R., Alvarez C., Miller J.I., et al. A&#xa0;mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7410499</ArticleId><ArticleId IdType="pubmed">32633718</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlin D.A., Gulick R.M., Martinez F.J. Severe COVID-19. N&#xa0;Engl J Med. 2020;383:2451&#x2013;2460.</Citation><ArticleIdList><ArticleId IdType="pubmed">32412710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R., Prasad V., McCarthy E.T., et al. Chymase increases glomerular albumin permeability via protease-activated receptor-2. Mol Cell Biochem. 2007;297:161&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">17102904</ArticleId></ArticleIdList></Reference><Reference><Citation>Marceau F., Bachelard H., Bouthillier J., et al. Bradykinin receptors: agonists, antagonists, expression, signaling, and adaptation to sustained stimulation. Int Immunopharmacol. 2020;82:106305.</Citation><ArticleIdList><ArticleId IdType="pubmed">32106060</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Veerdonk F.L., Netea M.G., van Deuren M., et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213974</ArticleId><ArticleId IdType="pubmed">32338605</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy C.G., Wilczynski S., Wenceslau C.F., et al. A&#xa0;new storm on the horizon in COVID-19: bradykinin-induced vascular complications. Vascul Pharmacol. 2021;137:106826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834250</ArticleId><ArticleId IdType="pubmed">33358968</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoneaux R., Shafer S.L. A&#xa0;RAS and bradykinin-mediated mechanism for COVID-19. ASA Monitor. 2020;84:1&#x2013;11.</Citation></Reference><Reference><Citation>Bernard I., Limonta D., Mahal L.K., et al. Endothelium infection and dysregulation by SARS-CoV-2: evidence and caveats in COVID-19. Viruses. 2020;13:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7823949</ArticleId><ArticleId IdType="pubmed">33375371</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardu C., Gambardella J., Morelli M.B., et al. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J&#xa0;Clin Med. 2020;9:1417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290769</ArticleId><ArticleId IdType="pubmed">32403217</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P.P., Blet A., Smyth D., et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation. 2020;142:68&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">32293910</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni G.N., Lala A., Bagiella E., et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J&#xa0;Am Coll Cardiol. 2020;76:1815&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7449655</ArticleId><ArticleId IdType="pubmed">32860872</ArticleId></ArticleIdList></Reference><Reference><Citation>Oxley T.J., Mocco J., Majidi S., et al. Large-vessel stroke as a presenting feature of COVID-19 in the young. N&#xa0;Engl J Med. 2020;382:e60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7207073</ArticleId><ArticleId IdType="pubmed">32343504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Bai H., Chen X., et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J&#xa0;Thromb Haemost. 2020;18:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J. The versatile heparin in COVID-19. J&#xa0;Thromb Haemost. 2020;18:1020&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906146</ArticleId><ArticleId IdType="pubmed">32239799</ArticleId></ArticleIdList></Reference><Reference><Citation>von Meijenfeldt F.A., Havervall S., Adelmeijer J., et al. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. Res Pract Thromb Haem. 2021;5:132&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845083</ArticleId><ArticleId IdType="pubmed">33537537</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons S., Fodil S., Azoulay E., et al. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care. 2020;24:353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296907</ArticleId><ArticleId IdType="pubmed">32546188</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P., Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41:3038&#x2013;3044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H., Pappas C., Belser J.A., et al. Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection. J&#xa0;Virol. 2012;86:667&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3255832</ArticleId><ArticleId IdType="pubmed">22072765</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittmann S., Weissenstein A., Villalon G., et al. Simultaneous treatment of COVID-19 with serine protease inhibitor camostat and/or cathepsin l inhibitor? J&#xa0;Clin Med Res. 2020;12:320&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239585</ArticleId><ArticleId IdType="pubmed">32489508</ArticleId></ArticleIdList></Reference><Reference><Citation>Boras B., Jones R.M., Anson B.J., et al.  Discovery of a novel inhibitor of Coronavirus 3CL protease for the potential treatment of COVID-19. bioRxiv. https://doi.org/10.1101/2020.09.12.293498 Published online February 12, 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.09.12.293498</ArticleId></ArticleIdList></Reference><Reference><Citation>El Amri C. Serine protease inhibitors to treat lung inflammatory diseases. Adv Exper Med Biol. 2021;1304:215&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">34019272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunst J.D., Staerke N.B., Pahus M.H., et al. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with COVID-19&#x2014;a double-blind randomized controlled trial. EClinicalMedicine. 2021;35:100849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8060682</ArticleId><ArticleId IdType="pubmed">33903855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney M., Damalanka V.C., Tartell M.A., et al. A&#xa0;novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells. Proc Natl Acad Sci U S A. 2021;118</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8694051</ArticleId><ArticleId IdType="pubmed">34635581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapira T., Monreal I.A., Dion S.P., et al.  A&#xa0;novel highly potent inhibitor of TMPRSS2-like proteases blocks SARS-CoV-2 variants of concern and is broadly protective against infection and mortality in mice. bioRxiv. https://doi.org/10.1101/2021.05.03.442520 Published online May 4, 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.03.442520</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers R.C. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153(suppl 1):S367&#x2013;S378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268072</ArticleId><ArticleId IdType="pubmed">18223674</ArticleId></ArticleIdList></Reference><Reference><Citation>Jose R.J., Williams A.E., Chambers R.C. Proteinase-activated receptors in fibroproliferative lung disease. Thorax. 2014;69:190&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">24186921</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercer P.F., Chambers R.C. Coagulation and coagulation signalling in fibrosis. Biochim Biophys Acta. 2013;1832:1018&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">23298546</ArticleId></ArticleIdList></Reference><Reference><Citation>Han E.D., MacFarlane R.C., Mulligan A.N., et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J&#xa0;Clin Invest. 2002;109:1057&#x2013;1063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC150945</ArticleId><ArticleId IdType="pubmed">11956243</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni H.S., Atkinson J.P. Targeting complement activation in COVID-19. Blood. 2020;136:2000&#x2013;2001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596848</ArticleId><ArticleId IdType="pubmed">33119763</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Chen L., Zang J., et al. C3a and C5a receptor antagonists ameliorate endothelial-myofibroblast transition via the Wnt/&#x3b2;-catenin signaling pathway in diabetic kidney disease. Metabolism. 2015;64:597&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">25682062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Sahu S.K., Cano M., et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol. 2021;6:eabh2259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158979</ArticleId><ArticleId IdType="pubmed">34446527</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomson T.M., Toscano-Guerra E., Casis E., et al. C1 esterase inhibitor and the contact system in COVID-19. Br J Haematol. 2020;190:520&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323335</ArticleId><ArticleId IdType="pubmed">32531085</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Yuan X., Chen H., et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136:2080&#x2013;2089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596849</ArticleId><ArticleId IdType="pubmed">32877502</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarjus A., Mart&#xed;nez-Mart&#xed;nez E., Amador C., et al. Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids. Hypertension. 2015;66:158&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">25987661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox C.S., Pitt B. Is spironolactone the preferred renin-angiotensin-aldosterone inhibitor for protection against COVID-19? J&#xa0;Cardiovasc Pharmacol. 2021;77:323&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pubmed">33278189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadegiani F.A., McCoy J., Gustavo Wambier C., et al. Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and time-to-remission in males with COVID-19: a randomized, double-blind, placebo-controlled interventional trial&#xa0;(EAT-DUTA AndroCoV trial - biochemical) Cureus. 2021;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7885746</ArticleId><ArticleId IdType="pubmed">33643746</ArticleId></ArticleIdList></Reference><Reference><Citation>Goren A., Wambier C.G., Herrera S., et al. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. J&#xa0;Eur Acad Dermatol Venereol. 2021;35:e13&#x2013;e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536996</ArticleId><ArticleId IdType="pubmed">32977363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wambier C.G., Goren A., Va&#xf1;o-Galv&#xe1;n S., et al. Androgen sensitivity gateway to COVID-19 disease severity. Drug Dev Res. 2020;81:771&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273095</ArticleId><ArticleId IdType="pubmed">32412125</ArticleId></ArticleIdList></Reference><Reference><Citation>Wambier C.G., Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J&#xa0;Am Acad Dermatol. 2020;83:308&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7151476</ArticleId><ArticleId IdType="pubmed">32283245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahl D.J., Hutchings K.M., Lisabeth E.M., et al. 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic acids: a highly potent new class of inhibitors of Rho/myocardin-related transcription factor (MRTF)/serum response&#xa0;factor (SRF)-mediated gene transcription as potential&#xa0;antifibrotic agents for scleroderma. J&#xa0;Med Chem. 2019;62:4350&#x2013;4369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590913</ArticleId><ArticleId IdType="pubmed">30951312</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Daly M., Pulakazhi Venu V.K., Saifeddine M., et al. Hyperglycaemic impairment of PAR2-mediated vasodilation: prevention by inhibition of aortic endothelial sodium-glucose-co-transporter-2 and minimizing oxidative stress. Vascul Pharmacol. 2018;109:56&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">29908295</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulakazhi Venu V.K., El-Daly M., Saifeddine M., et al. Minimizing hyperglycemia-induced vascular endothelial dysfunction by inhibiting endothelial sodium-glucose cotransporter 2 and attenuating oxidative stress: implications for treating individuals with type 2 diabetes. Can J Diabetes. 2019;43:510&#x2013;514.</Citation><ArticleIdList><ArticleId IdType="pubmed">30930073</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones S.A., Hunter C.A. Is IL-6 a key cytokine target for therapy in COVID-19? Nat Rev Immunol. 2021;21:337&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8043092</ArticleId><ArticleId IdType="pubmed">33850327</ArticleId></ArticleIdList></Reference><Reference><Citation>Malgie J., Schoones J.W., Pijls B.G. Decreased mortality in coronavirus disease 2019 patients treated with tocilizumab: a rapid systematic review and meta-analysis of observational studies. Clin Infect Dis. 2021;72:e742&#x2013;e749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543350</ArticleId><ArticleId IdType="pubmed">32964913</ArticleId></ArticleIdList></Reference><Reference><Citation>Mather K.J., Verma S., Anderson T.J. Improved endothelial function with metformin in type 2 diabetes mellitus. J&#xa0;Am Coll Cardiol. 2001;37:1344&#x2013;1350.</Citation><ArticleIdList><ArticleId IdType="pubmed">11300445</ArticleId></ArticleIdList></Reference><Reference><Citation>Park C.S., Bang B.R., Kwon H.S., et al. Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase. Biochem Pharmacol. 2012;84:1660&#x2013;1670.</Citation><ArticleIdList><ArticleId IdType="pubmed">23041647</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulakazhi Venu V.K., Saifeddine M., Mihara K., et al. Metformin prevents hyperglycaemia-associated, oxidative stress-induced vascular endothelial dysfunction: essential role for the orphan nuclear receptor, Nr4a1 (Nur77) Mol Pharmacol. 2021;100:428&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">34452975</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangarajan S., Bone N.B., Zmijewska A.A., et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat Med. 2018;24:1121&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6081262</ArticleId><ArticleId IdType="pubmed">29967351</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Libby P., Ridker P.M. COVID-19&#x2014;a vascular disease. Trends Cardiovasc Med. 2021;31:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7556303</ArticleId><ArticleId IdType="pubmed">33068723</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Ji W., Yang H., et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5:293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758411</ArticleId><ArticleId IdType="pubmed">33361764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista-Becerril B., Campi-Caballero R., Sevilla-Fuentes S., et al. Immunothrombosis in COVID-19: implications of neutrophil extracellular traps. Biomolecules. 2021;11:694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148218</ArticleId><ArticleId IdType="pubmed">34066385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriram K., Insel P.A. Inflammation and thrombosis in COVID-19 pathophysiology: proteinase-activated and purinergic receptors as drivers and candidate therapeutic targets. Physiol Rev. 2021;101:545&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238137</ArticleId><ArticleId IdType="pubmed">33124941</ArticleId></ArticleIdList></Reference><Reference><Citation>Holers V.M. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">24499275</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomopoulou K., Ricklin D., Ward P.A., et al. Interactions between coagulation and complement&#x2014;their role in inflammation. Semin Immunopathol. 2012;34:151&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372068</ArticleId><ArticleId IdType="pubmed">21811895</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomopoulou K., DeAngelis R.A., Chen H., et al. Induction of complement C3a receptor responses by kallikrein-related peptidase 14. J&#xa0;Immunol. 2013;191:3858&#x2013;3866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3922206</ArticleId><ArticleId IdType="pubmed">24014879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam L.K.M., Reilly J.P., Rux A.H., et al. Erythrocytes identify complement activation in patients with COVID-19. Am J Physiol Lung Cell Mol Physiol. 2021;321:L485&#x2013;L489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8384475</ArticleId><ArticleId IdType="pubmed">34231390</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg M.D., Epstein M. The innate immune response, microenvironment proteinases, and the COVID-19 pandemic: pathophysiologic mechanisms and emerging therapeutic targets. Kidney Int Suppl. 2022;12:48&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8931295</ArticleId><ArticleId IdType="pubmed">35316977</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovesdy C.P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073222</ArticleId><ArticleId IdType="pubmed">35529086</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossing P. Clinical perspective&#x2014;evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Kidney Int Suppl. 2022;12:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073226</ArticleId><ArticleId IdType="pubmed">35529090</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: an extraordinary paradigm shift. Kidney Int Suppl. 2022;12:1&#x2013;6.</Citation></Reference><Reference><Citation>Epstein M. Considerations for the future: current and future treatment paradigms with mineralocorticoid receptor antagonists&#x2014;unmet needs and underserved patient cohorts. Kidney Int Suppl. 2022;12:69&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9073253</ArticleId><ArticleId IdType="pubmed">35529085</ArticleId></ArticleIdList></Reference><Reference><Citation>LaVergne S.M., Stromberg S., Baxter B.A., et al. A&#xa0;longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae. BMC Infect Dis. 2021;21:677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8276222</ArticleId><ArticleId IdType="pubmed">34256735</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: an overview. Diabetes Metab Syndr. 2021;15:869&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Guler S.A., Ebner L., Aubry-Beigelman C., et al. Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study. Eur Respir J. 2021;57:2003690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8082329</ArticleId><ArticleId IdType="pubmed">33419891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezkalla S.H., Kloner R.A. Post-acute sequelae of SARS-COVID-2 syndrome: just the beginning. Cardiol Res. 2021;12:279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510656</ArticleId><ArticleId IdType="pubmed">34691325</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins V., Sohaei D., Diamandis E.P., et al. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021;58:297&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">33347790</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabacof L., Tosto-Mancuso J., Wood J., et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life and participation. Am J Phys Med Rehabil. 2022;101:48&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8667685</ArticleId><ArticleId IdType="pubmed">34686631</ArticleId></ArticleIdList></Reference><Reference><Citation>George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechowicz K., Drozdzal S., Machaj F., et al. COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J&#xa0;Clin Med. 2020;9:1917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356800</ArticleId><ArticleId IdType="pubmed">32575380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener M., Roldan N., Machahua C., et al. Human-based advanced in&#xa0;vitro approaches to investigate lung fibrosis and pulmonary effects of COVID-19. Front Med (Lausanne) 2021;8:644678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139419</ArticleId><ArticleId IdType="pubmed">34026781</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung H., Ramachandran R., Hollenberg M.D., et al. Proteinase-activated receptor-2 transactivation of epidermal growth factor receptor and transforming growth factor-&#x3b2; receptor signaling pathways contributes to renal fibrosis. J&#xa0;Biol Chem. 2013;288:37319&#x2013;37331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873584</ArticleId><ArticleId IdType="pubmed">24253040</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell D.C., Goldsack N.R., Marshall R.P., et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol. 2001;159:1383&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850500</ArticleId><ArticleId IdType="pubmed">11583966</ArticleId></ArticleIdList></Reference><Reference><Citation>Latouche C., El Moghrabi S., Messaoudi S., et al. Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system. Hypertension. 2012;59:966&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">22469622</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia G., Aroor A.R., Hill M.A., et al. Role of renin-angiotensin-aldosterone system activation in promoting cardiovascular fibrosis and stiffness. Hypertension. 2018;72:537&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6202147</ArticleId><ArticleId IdType="pubmed">29987104</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarjus A., Amador C., Michea L., et al. Vascular mineralocorticoid receptor and blood pressure regulation. Curr Opin Pharmacol. 2015;21:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">25733376</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuzawa N., Fujita T. The mineralocorticoid receptor in salt-sensitive hypertension and renal injury. J&#xa0;Am Soc Nephrol. 2021;32:279&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8054893</ArticleId><ArticleId IdType="pubmed">33397690</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonafine M., Martinez-Martinez E., Amador C., et al. Neutrophil gelatinase-associated lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. J&#xa0;Mol Cell Cardiol. 2018;115:32&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">29289651</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihara K., Ramachandran R., Renaux B., et al. Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1) J&#xa0;Biol Chem. 2013;288:32979&#x2013;32990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3829148</ArticleId><ArticleId IdType="pubmed">24052258</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R.M., Desai L.P. Reciprocal regulation of TGF-&#x3b2; and reactive oxygen species: a perverse cycle for fibrosis. Redox Biol. 2015;6:565&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4625010</ArticleId><ArticleId IdType="pubmed">26496488</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Yu X., Zhao H., et al. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7081524</ArticleId><ArticleId IdType="pubmed">32188484</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein S.L., Flanagan K.L. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F., Han M., Dai P., et al. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021;12:866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870838</ArticleId><ArticleId IdType="pubmed">33558541</ArticleId></ArticleIdList></Reference><Reference><Citation>Leach D.A., Mohr A., Giotis E.S., et al. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nat Commun. 2021;12:4068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8249423</ArticleId><ArticleId IdType="pubmed">34210968</ArticleId></ArticleIdList></Reference><Reference><Citation>Salah Z., Maoz M., Cohen I., et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J. 2005;19:62&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">15629896</ArticleId></ArticleIdList></Reference><Reference><Citation>Younis J.S., Skorecki K., Abassi Z. The double edge sword of testosterone&#x2019;s role in the COVID-19 pandemic. Front Endocrinol (Lausanne) 2021;12:607179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009245</ArticleId><ArticleId IdType="pubmed">33796068</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves M., Fernandes M.A., Bahat G., et al. Protecting older patients with cardiovascular diseases from COVID-19 complications using current medications. Eur Geriatr Med. 2021;12:725&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8143992</ArticleId><ArticleId IdType="pubmed">34031865</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.S., Lin P.C., Chen Y.S., et al. The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis. Ann Med. 2021;53:874&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8189130</ArticleId><ArticleId IdType="pubmed">34096808</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingo P., Mur I., Pomar V., et al. The four horsemen of a viral apocalypse: the pathogenesis of SARS-CoV-2 infection (COVID-19) EBioMedicine. 2020;58:102887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387269</ArticleId><ArticleId IdType="pubmed">32736307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragia G., Manolopoulos V.G. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies. Eur J Clin Pharmacol. 2020;76:1623&#x2013;1630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7372205</ArticleId><ArticleId IdType="pubmed">32696234</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Y., Lee H.M., Napolitano N., et al. 4-methoxycarbonyl curcumin: a unique inhibitor of both inflammatory mediators and periodontal inflammation. Mediators Inflamm. 2013;2013:329740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886587</ArticleId><ArticleId IdType="pubmed">24453415</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Alessandro E., Becker C., Bergmeier W., et al. Thrombo-inflammation in cardiovascular disease: an expert consensus document from the third Maastricht Consensus Conference on Thrombosis. Thromb Haemost. 2020;120:538&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">32289858</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S.P., Darbousset R., Schoenwaelder S.M. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133:906&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">30642917</ArticleId></ArticleIdList></Reference><Reference><Citation>Assinger A. COVID-19-related prothrombotic changes increase with lung injury and remain unaffected by anticoagulation therapy. Res Pract Thromb Haemost. 2021;5:11&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845064</ArticleId><ArticleId IdType="pubmed">33537524</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran R., Mihara K., Chung H., et al. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2) J&#xa0;Biol Chem. 2011;286:24638&#x2013;24648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137039</ArticleId><ArticleId IdType="pubmed">21576245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Kanthi Y., Knight J.S., et al. The interplay between neutrophils, complement, and microthrombi in COVID-19. Best Pract Res Clin Rheumatol. 2021;35:101661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831864</ArticleId><ArticleId IdType="pubmed">33526325</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A.M., Wysocki J., Batlle D. Interaction of SARS-CoV-2 and other coronavirus with ACE (angiotensin-converting enzyme)-2 as their main receptor: therapeutic implications. Hypertension. 2020;76:1339&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480804</ArticleId><ArticleId IdType="pubmed">32851855</ArticleId></ArticleIdList></Reference><Reference><Citation>Batlle D., Wysocki J., Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond) 2020;134:543&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">32167153</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall R.P., Gohlke P., Chambers R.C., et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004;286:L156&#x2013;L164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12754187</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow A., Glasgow J., Limonta D., et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117:28046&#x2013;28055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7668070</ArticleId><ArticleId IdType="pubmed">33093202</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsky T.W., Vergara R., Codina N., et al. De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2. Science. 2020;370:1208&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7920261</ArticleId><ArticleId IdType="pubmed">33154107</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteil V., Kwon H., Prado P., et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905&#x2013;913.e907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7181998</ArticleId><ArticleId IdType="pubmed">32333836</ArticleId></ArticleIdList></Reference><Reference><Citation>Soler M.J., Wysocki J., Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant. 2013;28:2687&#x2013;2697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3811059</ArticleId><ArticleId IdType="pubmed">23956234</ArticleId></ArticleIdList></Reference><Reference><Citation>Batlle D., Soler M.J., Sparks M.A., et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J&#xa0;Am Soc Nephrol. 2020;31:1380&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350999</ArticleId><ArticleId IdType="pubmed">32366514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocki J., Schulze A., Batlle D. Novel variants of angiotensin converting enzyme-2 of shorter molecular size to target the kidney renin angiotensin system. Biomolecules. 2019;9:886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6995632</ArticleId><ArticleId IdType="pubmed">31861139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysocki J., Ye M., Hassler L., et al. A&#xa0;novel soluble ACE2 variant with prolonged duration of action neutralizes SARS-CoV-2 infection in human kidney organoids. J&#xa0;Am Soc Nephrol. 2021;32:795&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017551</ArticleId><ArticleId IdType="pubmed">33526471</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel R.M., Majd H., Richter M.N., et al. Androgen signaling regulates&#xa0;SARS-CoV-2 receptor levels and is associated with severe&#xa0;COVID-19 symptoms in men. Cell Stem Cell. 2020;27:876&#x2013;889.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670929</ArticleId><ArticleId IdType="pubmed">33232663</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitzer T., Schlinzig T., Krohn K., et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673&#x2013;2678.</Citation><ArticleIdList><ArticleId IdType="pubmed">11723017</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">11742414</ArticleId></ArticleIdList></Reference><Reference><Citation>Tressel S.L., Kaneider N.C., Kasuda S., et al. A&#xa0;matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med. 2011;3:370&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394510</ArticleId><ArticleId IdType="pubmed">21591259</ArticleId></ArticleIdList></Reference><Reference><Citation>Foretz M., Guigas B., Bertrand L., et al. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20:953&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">25456737</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M., Xu H., Liu J., et al. Metformin and fibrosis: a review of existing evidence and mechanisms. J&#xa0;Diabetes Res. 2021;2021:6673525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102119</ArticleId><ArticleId IdType="pubmed">34007848</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jager J., Kooy A., Schalkwijk C., et al. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J&#xa0;Intern Med. 2014;275:59&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">23981104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>